We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
The Parenteral Drug Association (PDA) has just issued Technical Report no. 76: Identification and Classification of Visible Nonconformities in Elastomeric Components and Aluminum Seals for Parenteral Packaging.
This peer-reviewed document is especially intended for packaging manufacturers, and pharmaceutical companies that use rubber stoppers and aluminum seals with vials.
For the last four years, I co-chaired the task force of 24 industry experts who created this much-needed report, which standardizes terminology regarding components, designs and defects. Defects are described in detail: photographically, by location, and as critical/major/minor. This report will be a valuable resource in the pharmaceutical and packaging industries – for inspectors and those setting quality specifications.
To download, visit: https://store.pda.org/ProductCatalog/Product.aspx?ID=3441. PDA members may obtain this free through November 17.
<p><span>The overall quality of a final drug product depends on the components of its packaging and delivery systems. The use of visually inspected components reduces the risk of defective components and helps ensure patient safety.</span></p>
<strong>NovaPure® Components Overview</strong><br /><em>By leveraging nearly 100 years of pharmaceutical packaging knowledge and implementing Quality by Design principles, West has developed the continuously improving NovaPure® elastomer portfolio which can be ideal for all drug product phases.</em>
West is proud to announce that Diane Paskiet, Director, Scientific Affairs will serve as Co-chair at the upcoming PDA Packaging Conference in Baltimore, MD. In her leadership role for the meeting, Diane will moderate several sessions, including <em>Repackaging – Problems and Solutions</em> and <em>The Future Direction of Devices and Patient Adherence/Compliance</em>.
One factor of parenteral drug product quality is the container closure integrity (CCI) of the primary packaging system. The interaction between the sealing surface of the elastomeric component and the vial is vital to ensure stability of the drug product over the shelf life. Therefore, defects found on the elastomeric component can increase the risk of failure or end-of-the-line rejects.
Designed to help improve consistency and reliability of intradermal inject.
English
Chinese
